From initial FDA approvala
SINCE 2017, ≈253,000
PATIENTS HAVE FILLED AT
LEAST
1 DUPIXENT
PRESCRIPTIONb,c
a FDA approved since 2017 for adults, 2019 for adolescents (aged 12‑17 years), 2020 for children (aged 6-11 years),
and 2022 for infants to preschoolers (aged 6 months-5 years) with uncontrolled moderate‑to‑severe atopic dermatitis.
b IQVIA National Source of Business (NSOB) data as of April 2022.
c New adult and pediatric patients with uncontrolled moderate‑to‑severe atopic dermatitis.
Rapid and sustained results in adults
Your first-line systemic choice when topical Rx therapies are not enough for patients aged 6+ months with moderate-to-severe AD.
Revolutionizing the treatment for AD
patients on therapy
across approved indications worldwide1,b
best access
among specialty systemic therapies indicated for AD1,c-eStrong recommendation for the use of DUPIXENT in AAD and AAAAI/ACAAI Joint Task Force AD Guidelines2,3,f
A part of your standard of care for appropriate uncontrolled moderate-to-severe AD patients
aIQVIA SMART Portal Patient Insights as of June 2026.
bThe worldwide patient number is largely comprised of patients treated with DUPIXENT from 11 countries (Brazil, Canada, China, France, Germany, Italy, Japan, the Netherlands, Spain, UK, and US) and the rest of the world comprising ≈12% of this worldwide patient number. This number is composed of the following US approved indications: AD, asthma, BP, COPD, CRSwNP, CSU, PN, and EoE. Data through March 2026.
c≈96% of commercial AD patients (6+ months of age) nationally are covered for DUPIXENT. ≈89% of commercial AD patient lives have to fail only 1 or 2 prescription topical treatments.
dMMIT Analysis, May 2026. Analysis included DUPIXENT, tralokinumab, upadacitinib, abrocitinib, labrikizumab, and nemolizumab.
eBased on available published commercial UM coverage criteria.
fInclusion in AAD and AAAAI/ACAAI AD Guidelines does not denote endorsement or recommendation of product use by AAD and AAAAI/ACAAI.
First and only dual inhibitor of IL-4 and IL-13 signaling, two of the key drivers of type 2 inflammation4
The mechanism of dupilumab action has not been definitively established.
Studied in important populations aged 12+ years with uncontrolled, moderate-to-severe atopic dermatitis5,6
Patients with skin of color5
A phase 4, open-label study of patients with Fitzpatrick skin types IV, V, or VI
Patients with hand and/or foot involvement6
First specialty systemic therapy with a phase 3 trial in this patient population
DUPIXENT has a demonstrated long-term safety profile4
The Week 52 safety profile of DUPIXENT + TCS in adults was generally consistent with the Week 16 safety profile in adults.
Most common adverse reactions (incidence ≥1%) in patients with atopic dermatitis are injection site reactions, conjunctivitis, blepharitis, oral herpes, keratitis, eye pruritus, other herpes simplex virus infection, dry eye, and eosinophilia.
Other attributes and considerations
NOT AN
IMMUNOSUPPRESSANT
OR A STEROID4
NO KNOWN
DRUG-TO-DRUG
INTERACTIONS4
Not metabolized through the liver or excreted through the kidneys
NO INITIAL LAB TESTING OR ONGOING LAB MONITORING
according to the Prescribing Information4
NO BOXED WARNING4
Please see additional Warnings and Precautions in the Prescribing Information and Important Safety Information below.
SELECT IMPORTANT SAFETY INFORMATION
WARNINGS AND PRECAUTIONS
Hypersensitivity: Hypersensitivity reactions, including anaphylaxis, acute generalized exanthematous pustulosis (AGEP), serum sickness or serum sickness-like reactions, angioedema, generalized urticaria, rash, erythema nodosum, and erythema multiforme have been reported. A case of AGEP was reported in an adult subject who participated in the bullous pemphigoid development program. If a clinically significant hypersensitivity reaction occurs, institute appropriate therapy and discontinue DUPIXENT.
DUPIXENT MyWay is a patient support program that can help enable access to DUPIXENT and offers financial assistance for eligible patients, one-on-one nursing support, and more.
AAAAI, American Academy of Allergy, Asthma, and Immunology; AAD, American Academy of Dermatology; ACAAI, American College of Allergy, Asthma, and Immunology; BP, bullous pemphigoid; COPD, chronic obstructive pulmonary disease; CRSwNP, chronic rhinosinusitis with nasal polyps; CSU, chronic spontaneous urticaria; EoE, eosinophilic esophagitis; PN, prurigo nodularis; TCS, topical corticosteroids.